Physician profile
Parth P Patel
NPI 1578091096
$4,224.09
in general payments reported to CMS, 2019-2025
16 companies · $1,008 in 2025
The $1,008 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $117 · 2021: $224 · 2022: $764 · 2023: $1,810 · 2024: $301 · 2025: $1,008.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,737 · Grant: $1,126 · Education: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,736.67 |
| Grant | $1,126.43 |
| Education | $256.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,204.24 | 2022-2025 | Onyx Frontier, Linq II, Symplicity G3 |
| Boston Scientific Corporation | $1,126.43 | 2023 | |
| Abbott Laboratories | $346.40 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $304.81 | 2020-2022 | |
| Acist Medical Systems, INC. | $291.16 | 2023 | |
| Astellas Pharma US INC | $250.99 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.71 | 2025 | Jardiance |
| Asahi Intecc USA, INC. | $155.33 | 2023 | Asahi Ptca Guide Wire |
| Chiesi USA, INC. | $100.28 | 2022-2024 | Kengreal, Cleviprex |
| Kestra Medical Technology Services, INC. | $80.22 | 2024 | Assure Wcd |
| Philips North America LLC | $69.89 | 2025 | Ambulatory Monitoring & Diagnostics Undivided, Lm Undivided |
| Lilly USA, LLC | $33.69 | 2025 | Jardiance |
| Recordati_rare_diseases_inc. | $28.93 | 2025 | Isturisa |
| Glaxosmithkline, LLC. | $23.27 | 2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $21.36 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.38 | 2025 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parth Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.